Targeted enzyme prodrug therapies

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Cancer treatment faces challenges with invasive, metastatic, and inaccessible tumors despite traditional methods like surgery, chemotherapy, and radiotherapy.
• Targeted therapies have emerged over the last three decades to specifically locate, detect, and eliminate tumor cells.
• Tumor site-specific prodrug activation is a promising two-step targeted therapy approach.

Purpose of the Study:

• To provide a concise overview of the history and latest developments in targeted cancer therapies.
• To review key technologies in targeted cancer treatment, focusing on enzyme prodrug strategies.
• To highlight advancements in prodrug-converting enzymes, prodrugs, and drugs for cancer therapy.

Main Methods:

• Review of historical and recent scientific literature on targeted cancer therapies.
• Analysis of enzyme prodrug therapy concepts and their evolution since 1974.
• Examination of various targeting systems including antibody-directed enzyme prodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), clostridial- (CDEPT), and polymer-directed enzyme prodrug therapy (PDEPT).

Main Results:

• Significant progress has been made in developing targeted therapies, particularly those involving enzyme-mediated prodrug activation.
• Various targeting systems, enzymes, and prodrugs have been investigated and refined over the years.
• The review covers a range of enzyme prodrug therapy approaches and their components.

Conclusions:

• Enzyme prodrug therapy represents a significant advancement in the quest for more effective and specific cancer treatments.
• Continued research and development in targeting systems, enzymes, and prodrugs are crucial for overcoming challenges in cancer cure.
• Targeted therapies, especially ADEPT and GDEPT, offer a promising alternative for treating difficult cancers.